Cannovum Health welcomes new strategic majority investor – Triple Crown Ventures becomes main shareholder
more
Stories about Pharmaindustrie
Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
Leobendorf, Austria (ots/PRNewswire) - Saypha® injectables to launch in the U.S. under the Obagi Medical brand, expanding global reach of Croma's science-driven aesthetic solutions Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture ...
moreABDA Bundesvgg. Dt. Apothekerverbände
Germany’s pharmacies under pressure: Statistical Yearbook 2025 now available
Berlin (ots) - ABDA – Federal Union of German Associations of Pharmacists has released the Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2025”. The publication offers a comprehensive overview of the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond. It shows that the number of pharmacies has decreased again. At the ...
moreIchnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
moreLTS Lohmann Therapie-Systeme AG
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
Andernach / Montreal (ots) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality ...
moreIsomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence
London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...
more
Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250
Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...
more- 3
Key technology for bioprocesses
more BIAL Announces Oral Presentation at GBA1 Meeting 2025
Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...
moreGrünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
moreASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
Petach Tikva, Israel (ots/PRNewswire) - ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential ...
moreMaren Thurow starts as new Head Global Communications at Grünenthal
more
NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response
Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...
moreBiomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase
Vienna, Austria (ots) - Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a ...
moreBiomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site
moreAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
moreCentor Launches Smart Pill Organizer to Support Medication Adherence
moreGerresheimer: Bormioli Pharma boosts revenues and earnings
Düsseldorf (ots) - - Revenues +11.6%, Adjusted EBITDA +13.1% - Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% - Q1 significantly influenced by revenue shift in syringe business - Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of 22% Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and ...
more
Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS
Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...
moreFinancial Year 2024: Weleda Achieves Record Turnover and Significantly Improves Profitability
moreSHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market
moreIsomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
moreIsomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
more- 3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
One documentmore
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
moreMIDEUROPA-BACKED DIAGNOSTYKA MAKES ITS WARSAW STOCK EXCHANGE DEBUT
London (ots/PRNewswire) - MidEuropa, a leading private equity investor with deep roots in Central Europe, announces that its portfolio company, Diagnostyka, a leading provider of medical diagnostic services in Poland, has debuted on the Warsaw Stock Exchange on Friday, February 7, 2025. The market closing price on the first day of trading puts Diagnostyka's market capitalisation at over €1 billion. Diagnostyka thus ...
moreLyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights
Basel, Switzerland (ots/PRNewswire) - Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced a transformative collaboration with EVERSANA®, a leading provider of global commercial services to the life sciences industry, to revolutionize drug pricing and access through artificial intelligence-driven insights. By combining data ...
moreX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
moreKeith Hale appointed as Group CEO to Unite Titian Software & Labguru (BioData)
London (ots/PRNewswire) - Keith Hale has been appointed as Group CEO of Titian Software and Labguru (BioData Inc.), two leading providers of laboratory data management solutions, as part of the goal to accelerate the future of digital lab operations. A well-known fintech executive, Keith brings 33 years of growth-focused software and technology leadership. He ...
moreLTS Lohmann Therapie-Systeme AG
LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships
more
123456Next